Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Moderate and Severe Plaque Psoriasis
Interventions: Placebo, AEB071; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 10
States / cities: Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more

Conditions: Psoriasis
Interventions: Bicillin L-A; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Psoriasis
Interventions: Mirikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Farmington, Connecticut • Coral Gables, Florida • Ocala, Florida + 7 more

Conditions: Arthritis, Psoriatic
Interventions: Tofacitinib, Methotrexate, Placebo Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more

Conditions: Generalized Pustular Psoriasis
Interventions: 750 mg Imsidolimab, 300 mg Imsidolimab, Placebo; Drug · Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more

Conditions: Psoriasis
Interventions: Clobetasol Propionate, 0.05%, Clobetasol propionate, 0.05% Spray; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Cedar Knolls, New Jersey

Conditions: Psoriasis
Interventions: Trichuris Suis Ova; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Plaque Psoriasis
Interventions: 188-0551 Spray, Vehicle Spray; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Los Angeles, California • Ocala, Florida • Macon, Georgia + 11 more

Conditions: Psoriasis
Interventions: IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Anaheim, California • Encino, California • San Diego, California + 9 more

Conditions: Psoriasis
Interventions: No Intervention; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 12
States / cities: Bakersfield, California • Los Angeles, California • Ocala, Florida + 9 more

Conditions: Psoriasis
Interventions: Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Bakersfield, California • Irvine, California + 37 more

Conditions: Plaque Psoriasis
Interventions: 000-0551 Lotion, Vehicle Lotion; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 10
States / cities: Fremont, California • San Diego, California • Arlington Heights, Illinois + 7 more

Conditions: Plaque Psoriasis
Interventions: LEXETTE 0.05% Topical Foam, Sorilux 0.005 % Topical Foam, Vehicle Foam; Drug · Other
Lead sponsor: Skin Sciences, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions: Creating Health Online Course, Delayed access to Creating Health Online Course; Behavioral
Lead sponsor: Terry L. Wahls; Other
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Fremont, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Conditions: Psoriasis, Atopic Dermatitis, Acne
Interventions: Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions: Pharmacokinetics of certolizumab pegol; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma

Conditions: Psoriasis
Interventions: Saliva or buccal sample; Other
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psoriasis
Interventions: Prurisol, Ziagen; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Psoriasis
Interventions: Enstilar; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Psoriasis
Interventions: CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo; Drug
Lead sponsor: Janssen Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Phoenix, Arizona • San Diego, California • Tustin, California + 30 more

Conditions: Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions: ASP015K; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Plaque Psoriasis
Interventions: ME3183, Placebo; Drug
Lead sponsor: Meiji Pharma USA Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 11 more

Search by objective public record fields.

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

An Exploratory Genetic Study in Participants With Psoriasis

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Genetic Analysis of Pediatric Psoriasis

Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers

Taltz in Combination With Enstilar for Psoriasis

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis